Promising new drug for treatment-resistant depression – esketamine
One in 3 people with severe depression do not respond to treatment. Credit: TZIDO SUN/Shutterstock.com...
Health News 2 me
healthnews2me.com
Category: Medications
Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019 /PRNewswire/ -- Praluent (alirocumab) will be made...
Study finds rise in overdoses from opioids in diarrhea drug
A Rutgers study has uncovered a new threat in the opiate epidemic: Overdoses of loperamide,...
FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
BRIDGEWATER, N.J., Jan. 23, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved...
Research into opioid painkillers could provide clues for safer drug development
Researchers have taken a step closer to understanding the body's response to opioid painkillers such...
Opioids now more deadly for Americans than traffic accidents
(HealthDay)—For the first time in history, Americans' risk for dying from an opioid overdose is...
FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved...
Study examines the course of back pain over time
Back pain is among the most frequently reported health problems in the world. New research...
Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
January 3, 2019 -- Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase...
Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate
Saint-Herblain (France), December 21, 2018 - Valneva SE ("Valneva"), a biotech company developing and commercializing...